GenPath logo in conjunction with women's health

Hereditary Cancer Testing

Our sister company, GeneDx, a subsidiary of BioReference Laboratories, Inc. and an OPKO Health company, has developed comprehensive panels to test key genes associated with increased susceptibility to many cancer sub-types.

With high quality testing, expertise, and experience, GeneDx has performed over 184,000 hereditary cancer tests to date

GeneDx Is A Pioneer In The Inherited Disorders Industry

  • GeneDx was the first to commercially launch next-generation sequencing (NGS) in 2008
  • GeneDx co-founders are thought-leaders and are co-authors of established guidelines, such as the ACMG guidelines on NGS

GeneDx Development Timeline

GenPath Hereditary Cancer Panels Provide Accurate Results With Industry-Leading Turn-Around Times

View test options for hereditary cancer panels

*Testing includes sequencing and deletion duplication for all genes except EPCAM (del/dup only),
MITF (evaluation of c.952G>A only), and SCG5/GREM1 (del/dup only).

See a complete list of hereditary cancer panels offered by GeneDx:

Learn More

©2019 GenPath, a division of BioReference Laboratories Inc., an OPKO Health Company